Page last updated: 2024-09-03

tazobactam and Cross Infection

tazobactam has been researched along with Cross Infection in 76 studies

Research

Studies (76)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (11.84)	18.2507
2000's	25 (32.89)	29.6817
2010's	30 (39.47)	24.3611
2020's	12 (15.79)	2.80

Authors

Authors	Studies
De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A	1
Adalia, R; Aguilar, G; Azanza, JR; Barberán, J; Borges, M; Bou Arévalo, G; Cardinal-Fernández, P; Estella, A; Fernández Gómez, J; Ferrer, R; González de Molina, FJ; León López, R; LLinares Mondéjar, P; Marco, F; Maseda, E; Mensa, J; Oliver, A; Pasquau, J; Poliakova, Y; Rascado, P; Robles Marcos, MS; Salavert, M; Serrano García, R; Soriano, A	1
Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M	1
Ballesta, S; López, CE; López-Cerero, L; Pascual, A; Rojo-Martin, MD; Sánchez-Yebra, W	1
Bautista, J; Beique, L; Cayen, J; Choi, K; Comeau, JL; Conly, J; Dalton, B; Delport, J; Dhami, R; Embree, J; Émond, Y; Evans, G; Frenette, C; Fryters, S; Happe, J; Katz, K; Kibsey, P; Langley, JM; Lee, BE; Lefebvre, MA; Leis, JA; McGeer, A; McKenna, S; Neville, HL; Pelude, L; Rudnick, W; Science, M; Slayter, K; Suh, KN; Thirion, DJG; Tse-Chang, A; Weiss, K	1
Autmizguine, J; Kassir, N; Lavigne, J; Litalien, C; Théorêt, Y; Thibault, C	1
Bou, G; Cabot, G; Cortes-Lara, S; Del Barrio-Tofiño, E; López-Causapé, C; Martínez-Martínez, L; Oliver, A; Sánchez-Diener, I; Zamorano, L	1
Bruno, CJ; Butterton, JR; Huntington, JA; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B	1
Kalil, AC; Zavascki, AP	1
Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG	1
Lai, CC; Tang, HJ	1
Bassetti, M; Cattelan, A; Giacobbe, DR; Mussini, C; Vena, A	1
Karlowsky, JA; Kazmierczak, KM; Motyl, MR; Sahm, DF; Young, K	1
Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H	1
Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D	1
Asensio-Martín, MJ; Balandin, B; Ballesteros, D; Chicot, M; Fernández-Simón, I; Iranzo, R; López-Vergara, L; Martínez-Sagasti, F; Pérez-Pedrero, MJ; Pintado, V; Rodríguez-Serrano, D; Royuela, A; Ruiz de Luna, R; Sancho-González, M; Silva, A; Soriano-Cuesta, C	1
Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N	1
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y	1
Grupper, M; Nicolau, DP; Sutherland, C	1
Lodise, TP; Natesan, S; Pai, MP	1
Arena, F; Bassetti, M; D'Andrea, MM; Di Pilato, V; Giani, T; Henrici De Angelis, L; Pollini, S; Rossolini, GM	1
Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG	2
Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K	1
Cronin, K; Engler, C; Norton, R; Parsonson, F; Slack, A	1
Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J	1
Basak, GW; Saran, O; Sulik-Tyszka, B; Wróblewska, MM	1
Li, J; Ma, W; Sun, S; Wang, D; Yu, C	1
Boulanger, B; Cizeau, F; Decousser, JW; Ducellier, D; Fourreau, F; Mercier-Darty, M; Mongardon, N; Podglajen, I; Potron, A; Royer, G	1
Choi, EH; Lee, HJ; Lee, J; Oh, CE	1
Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS	2
Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS	1
Du, Y; Guo, W; He, J; He, Q; Wang, Z; Wei, M; Wu, C; Yang, Z	1
Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL	1
Nicolau, DP; Sutherland, CA	1
Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ	1
Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S	1
Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA	1
Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E	1
Aldeyab, MA; Bailie, R; Elshibly, SM; Hanley, J; Hughes, CM; Kearney, MP; McDowell, DA; McElnay, JC; McMahon, MA; Scott, MG	1
Cotter, M; Crowley, B; O Connell, N; Roche, C	1
Drusano, GL; Lodise, TP; Patel, N; Scheetz, MH	1
Bulik, CC; Christensen, H; Nicolau, DP	1
Chander, J; Garg, R; Gulati, N; Gupta, V; Krishnan, P; Kumarasamy, K	1
Alos, JI; Gomez-Garces, JL; Hernaiz, C; Picardo, A	1
Ahern, JW; Alston, WK	1
Apfalter, P; Berger, A; Kretzer, V; Pollak, A; Rohrmeister, K; Zaknun, D	1
Danziger, LH; Drusano, GL; Lodise, TP; Lomaestro, B; Rodvold, KA	1
Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S	1
Rice, LB	1
Leitner, E; Lode, H; Schmitt, DV; Welte, T	1
Avlamis, A; Daikos, GL; Markogiannakis, A; Papaparaskevas, J; Papapareskevas, J; Petrikkos, G; Stefanakos, G; Zissis, NP	1
Tucker, H; Wu, D	1
Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN	1
Braga, AL; Burattini, MN; Jukemura, EM; Medeiros, EA; Pereira, CA	1
Barnaud, G; Chevrel, G; Dreyfuss, D; Eveillard, M; Meybeck, A; Mounier, R; Ricard, JD	1
Betschel, S; Kreiswirth, B; Low, DE; Willey, BM	1
Sanders, CV	1
Adhikari, M; Pillay, DG; Pillay, T; Sturm, AW	1
Bianchi, C; Bonfiglio, G; Nicoletti, G; Stefani, S; Zollo, A	1
Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G	1
Birawska, I; Fuchs, J; Szulakowska, E	1
Corrado, OJ; Fawley, WN; Hawkey, PM; Settle, CD; Wilcox, MH	1
Lessing, MP; Stewart, BA	1
Miranda, E; Sader, HS; Sejas, L; Tosin, I	1
Bradley, SJ	1
Cross, JM; May, AK; McGwin, G; Melton, SM; Moser, SA; Rue, LW	1
Mohammedi, I; Tigaud, S; Tournadre, JP	1
Coia, JE; Gillespie, TA; Hanson, MF; Johnson, PR; Notman, AW	1
O'Connell, M; Petros, AJ; Roberts, C; van Saene, HK; Wade, P	1
Allen, MC; Bradley, SJ; Goldstone, AH; Scott, GM; Sher, HA; Wilson, AL	1
Abi-Said, D; Bivins, C; Hachem, R; Hanna, H; Huaringa, A; Raad, I; Sukumaran, A; Thornby, J; Walsh, G; Whimbey, E	1
Akhan, S; Coskunkan, F; Tansel, O; Vahaboglu, H	1
Harris, AD; Johnson, JA; Kaye, KS; Morris, G; Perencevich, E; Roghmann, MC	1
Cassone, M; Falcone, M; Paris, A; Pavoni, G; Pistella, E; Venditti, M	1

Reviews

4 review(s) available for tazobactam and Cross Infection

Article	Year
Ceftolozane-tazobactam in nosocomial pneumonia. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35 Suppl 1 Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam	2022
Antimicrobial resistance in gram-positive bacteria. The American journal of medicine, 2006, Volume: 119, Issue:6 Suppl 1 Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterococcus faecalis; Gastrointestinal Tract; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin Resistance	2006
Enterococcis: pathogens of the 90s. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:573 Topics: Abdominal Abscess; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Gram-Positive Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin	1994
[Piperacillin-tazobactam in the treatment of severe nosocomial infections]. Recenti progressi in medicina, 2002, Volume: 93, Issue:3 Topics: Bacteria; beta-Lactamase Inhibitors; Clinical Trials as Topic; Costs and Cost Analysis; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Tazobactam	2002

Trials

12 trial(s) available for tazobactam and Cross Infection

Article	Year
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. The Lancet. Infectious diseases, 2019, Volume: 19, Issue:12 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Tazobactam; Treatment Outcome	2019
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections	2017
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. Journal of clinical pharmacology, 2016, Volume: 56, Issue:1 Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Pneumonia; Tazobactam; Young Adult	2016
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Current medical research and opinion, 2008, Volume: 24, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome	2008
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:12 Topics: Algorithms; Computer Simulation; Cross Infection; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Models, Biological; Monte Carlo Method; Penicillanic Acid; Penicillins; Piperacillin; Population; Tazobactam	2004
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respiratory medicine, 2006, Volume: 100, Issue:9 Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome	2006
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. Infection, 2006, Volume: 34, Issue:3 Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome	2006
Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review. Intensive care medicine, 1994, Volume: 20 Suppl 3 Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam	1994
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:11 Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam	1998
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:12 Topics: Aged; beta-Lactamase Inhibitors; Cefotaxime; Clostridioides difficile; Cross Infection; Cross-Over Studies; Diarrhea; Drug Combinations; Enterocolitis, Pseudomembranous; Enzyme Inhibitors; Female; Humans; Male; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam	1998
The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Enterococcus; Female; Glycopeptides; Gram-Positive Bacterial Infections; Hematology; Hospital Units; Humans; Infection Control; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam	1999
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. Annals of surgical oncology, 2001, Volume: 8, Issue:2 Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Combination; Humans; Middle Aged; Neoplasms; Opportunistic Infections; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Postoperative Complications; Prognosis; Prospective Studies; Tazobactam	2001

Other Studies

60 other study(ies) available for tazobactam and Cross Infection

Article	Year
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections	2010
Recommendations for antibiotic selection for severe nosocomial infections. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021, Volume: 34, Issue:5 Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Humans; Tazobactam	2021
Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa. Enfermedades infecciosas y microbiologia clinica (English ed.), 2023, Volume: 41, Issue:10 Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
Antimicrobial use among paediatric inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program, 2017/2018. Antimicrobial resistance and infection control, 2023, 04-18, Volume: 12, Issue:1 Topics: Adult; Anti-Infective Agents; Canada; Cefazolin; Ceftriaxone; Child; Cross Infection; Hospitals; Humans; Infant, Newborn; Inpatients; Piperacillin; Tazobactam	2023
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:11 Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2019
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. The Journal of antimicrobial chemotherapy, 2019, 11-01, Volume: 74, Issue:11 Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Cross Infection; Drug Resistance, Multiple, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; O Antigens; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Serogroup; Serotyping; Spain; Tazobactam; Whole Genome Sequencing	2019
Can ceftolozane-tazobactam treat nosocomial pneumonia? The Lancet. Infectious diseases, 2019, Volume: 19, Issue:12 Topics: Cephalosporins; Cross Infection; Double-Blind Method; Humans; Meropenem; Pneumonia; Tazobactam	2019
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply. The Lancet. Infectious diseases, 2020, Volume: 20, Issue:1 Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam	2020
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia. The Lancet. Infectious diseases, 2020, Volume: 20, Issue:1 Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam	2020
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 10-23, Volume: 71, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome	2020
In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagnostic microbiology and infectious disease, 2020, Volume: 96, Issue:4 Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Escherichia coli; Escherichia coli Infections; Hospitalization; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Tazobactam	2020
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. International journal of antimicrobial agents, 2020, Volume: 55, Issue:6 Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2020
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. The Journal of antimicrobial chemotherapy, 2020, 10-01, Volume: 75, Issue:10 Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2020
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. International journal of antimicrobial agents, 2021, Volume: 57, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Tazobactam; Treatment Outcome	2021
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre. Le infezioni in medicina, 2017, Mar-01, Volume: 25, Issue:1 Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin	2017
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:10 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins	2017
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10 Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2017
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. The Journal of antimicrobial chemotherapy, 2018, 03-01, Volume: 73, Issue:3 Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Cephalosporins; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Italy; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Whole Genome Sequencing	2018
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. The Journal of antimicrobial chemotherapy, 2018, 03-01, Volume: 73, Issue:3 Topics: Canada; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2018
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients. Diagnostic microbiology and infectious disease, 2018, Volume: 92, Issue:1 Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam	2018
Activity of Ceftolozane-Tazobactam against The American journal of tropical medicine and hygiene, 2018, Volume: 99, Issue:2 Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Cephalosporins; Cross Infection; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Humans; Melioidosis; Microbial Sensitivity Tests; Tazobactam	2018
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019, Volume: 32, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam	2019
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland. Medical science monitor : international medical journal of experimental and clinical research, 2019, Jan-10, Volume: 25 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Patients; Poland; Pseudomonas; Pseudomonas Infections; Tazobactam	2019
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa. Letters in applied microbiology, 2019, Volume: 69, Issue:3 Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2019
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone. The Journal of hospital infection, 2020, Volume: 104, Issue:1 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cross Infection; Disease Outbreaks; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; France; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2020
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:8 Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam	2013
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11 Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam	2013
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). The Journal of infection, 2014, Volume: 69, Issue:3 Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Citrobacter; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Europe; Gram-Negative Aerobic Bacteria; Humans; Intraabdominal Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Proteus mirabilis; Pseudomonas aeruginosa; Serratia; Tazobactam; United States; Urinary Tract Infections	2014
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). International journal of antimicrobial agents, 2014, Volume: 43, Issue:6 Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam; United States	2014
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:10 Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2014
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China. American journal of infection control, 2015, Apr-01, Volume: 43, Issue:4 Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization Review; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers	2015
Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. European journal of drug metabolism and pharmacokinetics, 2016, Volume: 41, Issue:4 Topics: Anti-Bacterial Agents; Body Weight; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam	2016
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7 Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States	2015
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak. PloS one, 2015, Volume: 10, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam	2015
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections	2017
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit. International journal of antimicrobial agents, 2008, Volume: 32, Issue:6 Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretation, Statistical; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Hand Disinfection; Hygiene; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Personnel, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections; Tazobactam	2008
First identification of class A carbapenemase-producing Klebsiella pneumoniae in the Republic of Ireland. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2009, Apr-02, Volume: 14, Issue:13 Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Ireland; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam	2009
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Area Under Curve; Bayes Theorem; Cross Infection; Drug Combinations; Female; Hospitalization; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Reproducibility of Results; Tazobactam; United States; United States Food and Drug Administration	2010
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Young Adult	2010
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India. The Indian journal of medical research, 2012, Volume: 136, Issue:2 Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam	2012
Nosocomial bacteremia and catheter infection by Bacillus cereus in an immunocompetent patient. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2003, Volume: 9, Issue:9 Topics: Aged; Bacillaceae Infections; Bacillus cereus; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; Cross Infection; Digestive System Surgical Procedures; Drug Therapy, Combination; Humans; Immunocompetence; Male; Penicillanic Acid; Piperacillin; Tazobactam	2003
Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. The Journal of antimicrobial chemotherapy, 2004, Volume: 53, Issue:3 Topics: Clostridioides difficile; Cross Infection; Diarrhea; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; United States	2004
Safety evaluation of piperacillin/tazobactam in very low birth weight infants. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:2 Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Drug Therapy, Combination; Enterocolitis, Necrotizing; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Very Low Birth Weight; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome	2004
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospita International journal of antimicrobial agents, 2007, Volume: 29, Issue:1 Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Greece; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Prospective Studies; Tazobactam; Time Factors	2007
Appropriate comparators for alternate dosing strategies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Risk Assessment; Tazobactam; Treatment Outcome	2007
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. The Journal of trauma, 2007, Volume: 63, Issue:2 Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome	2007
Control of multi-resistant bacteria and ventilator-associated pneumonia: is it possible with changes in antibiotics? The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:4 Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Tazobactam	2007
Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study. BMC infectious diseases, 2008, May-17, Volume: 8 Topics: Anti-Bacterial Agents; beta-Lactamases; Cohort Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; France; Humans; Incidence; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Treatment Outcome	2008
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. American journal of perinatology, 1998, Volume: 15, Issue:1 Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Imipenem; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Protease Inhibitors; Retrospective Studies; Tazobactam; Thienamycins	1998
Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy. Drugs under experimental and clinical research, 1998, Volume: 24, Issue:2 Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Enzyme Inhibitors; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Italy; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam	1998
[Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam]. Medycyna doswiadczalna i mikrobiologia, 1998, Volume: 50, Issue:1-2 Topics: beta-Lactamase Inhibitors; Body Fluids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Tazobactam	1998
A hospital outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. The Journal of hospital infection, 1999, Volume: 41, Issue:1 Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam	1999
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2000, Volume: 4, Issue:1 Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Clavulanic Acid; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam; Ticarcillin	2000
Control of glycopeptide-resistant enterococci in an oncology unit. Pharmacotherapy, 2000, Volume: 20, Issue:9 Pt 2 Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cohort Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Glycopeptides; Humans; Infection Control; Neoplasms; Neutropenia; Oncology Service, Hospital; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome	2000
Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock (Augusta, Ga.), 2000, Volume: 14, Issue:3 Topics: Burn Units; Cephalosporins; Clinical Protocols; Cross Infection; Drug Utilization; Enterococcus; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Vancomycin; Vancomycin Resistance; Wounds and Injuries	2000
Emergence of piperacillin/tazobactam-resistant Escherichia coli. Intensive care medicine, 2000, Volume: 26, Issue:10 Topics: beta-Lactamase Inhibitors; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; France; Humans; Infection Control; Intensive Care Units; Patient Selection; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam	2000
Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2000, Volume: 6, Issue:3 Topics: Bacteremia; Cross Infection; Drug Resistance, Multiple; Enzyme Inhibitors; Hospitals, General; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Oncology Service, Hospital; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sanitary Engineering; Scotland; Species Specificity; Sputum; Tazobactam	2000
Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU. Chest, 2001, Volume: 119, Issue:3 Topics: Amikacin; beta-Lactamase Inhibitors; Cohort Studies; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Klebsiella; Klebsiella Infections; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam	2001
Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. Scandinavian journal of infectious diseases, 2001, Volume: 33, Issue:7 Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cross Infection; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Molecular Sequence Data; Penicillanic Acid; Penicillins; Piperacillin; Polymerase Chain Reaction; Tazobactam; Turkey	2001
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:3 Topics: Adult; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas Infections; Regression Analysis; Risk Factors; Tazobactam	2002